Fibromyalgia Market to Register Stunning Growth During the Forecast Period (2023-2032) – DelveInsight | Key Companies – AppliedVR, Aptinyx, Tryp Therapeutics, Scilex, Virios, TRYP Therapeutics, UCB

Fibromyalgia Market to Register Stunning Growth During the Forecast Period (2023-2032) - DelveInsight | Key Companies - AppliedVR, Aptinyx, Tryp Therapeutics, Scilex, Virios, TRYP Therapeutics, UCB
Delveinsight Business Research LLP
As per DelveInsight, the Fibromyalgia Market is anticipated to evolve immensely in the coming years owing to the increase in the number of patients in the 7MM and the launch of novel therapies in the market.

DelveInsight’s “Fibromyalgia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Fibromyalgia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Fibromyalgia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Fibromyalgia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Fibromyalgia: An Overview

Fibromyalgia, also known as fibromyalgia syndrome, is a prevalent and complex chronic pain illness that causes musculoskeletal pain, exhaustion, and localized soreness and has an impact on people’s emotional, physical, and social well-being. It is primarily caused by hereditary disorders, however, the exact reason is unknown.

The etiology and pathogenesis of fibromyalgia are still not fully understood. Several factors such as dysfunction of the central and autonomic nervous systems, neurotransmitters, hormones, immune system, external stressors, psychiatric aspects, and others seem to be involved

According to the European Network of Fibromyalgia Associations (ENFA), around 14 million people are affected in Europe by fibromyalgia, and approximately 400 million people globally.

Fibromyalgia Market Key Facts

  • According to the Worldwide Epidemiology of Fibromyalgia by Queiroz, the global mean prevalence of fibromyalgia was 2.7 % and the mean rate was 3.1 % in America, and 2.5 % in Europe while for Asia it was reported 1.7%.

  • According to the research study by White et al., an overall age- and sex-adjusted prevalence for FM was 3.3% (4.9% in women and 1.6% in men). It was also found that peak prevalence in men was found in middle age, whereas in women the prevalence steadily increases with age.

  • According to a study by Neumann et al., the prevalence of fibromyalgia in the general population was reported to range from 0.5% to 5% while the prevalence was up to 15.7% in the clinic.

Fibromyalgia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Fibromyalgia pipeline therapies. It also thoroughly assesses the Fibromyalgia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Fibromyalgia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Fibromyalgia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Fibromyalgia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Fibromyalgia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Fibromyalgia Epidemiology, Segmented as –

  • Total Prevalent Cases of Fibromyalgia (FM) in the 7MM [2019–2032]

  • Diagnosed and treatable Cases of Fibromyalgia (FM) in the 7MM [2019–2032]

  • Severity-specific Cases of Fibromyalgia (FM) in the 7MM [2019–2032]

  • Gender-specific Cases of Fibromyalgia (FM) in the 7MM [2019–2032]

Fibromyalgia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Fibromyalgia market or expected to be launched during the study period. The analysis covers the Fibromyalgia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Fibromyalgia drugs based on their sale and market share.

The report also covers the Fibromyalgia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Fibromyalgia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Fibromyalgia Market Will Evolve and Grow by 2032 @

Fibromyalgia Therapeutics Analysis

The treatments applied to FM are varied, and most often consist of a combination of medications with lifestyle changes. The majority of physicians use an empirical approach, varying the drugs and dosages they administer until they find what works best for each patient. Titrating drugs to find the optimal dose and using them in combinations that are found to provide optimal relief for each patient is the norm.

The FDA has approved three drugs to treat fibromyalgia—pregabalin (marketed as Lyrica), duloxetine (Cymbalta), and milnacipran (Savella). Lyrica is an anti-epileptic, while Cymbalta and Savella are antidepressants. Apart from these approved therapies, there are a variety of drugs and medications that treat the gamut of fibromyalgia symptoms.

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Fibromyalgia. Currently, Tonix Pharmaceuticals is leading the therapeutics market with its Fibromyalgia drug candidates in the most advanced stage of clinical development.

Fibromyalgia Companies Actively Working in the Therapeutics Market Include

  • AppliedVR, Inc.

  • Aptinyx

  • Axsome Therapeutics

  • Paradise Genomics

  • Scilex Holding Company

  • Tonix Pharmaceuticals

  • Tryp Therapeutics

  • UCB

  • Virios Therapeutics

And Many Others

Emerging and Marketed Fibromyalgia Therapies Covered in the Report Include:

  • IMC-1: Virios Therapeutics

  • TNX-102: Tonix Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Fibromyalgia Competitive Intelligence Analysis

4. Fibromyalgia Market Overview at a Glance

5. Fibromyalgia Disease Background and Overview

6. Fibromyalgia Patient Journey

7. Fibromyalgia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Fibromyalgia Treatment Algorithm, Current Treatment, and Medical Practices

9. Fibromyalgia Unmet Needs

10. Key Endpoints of Fibromyalgia Treatment

11. Fibromyalgia Marketed Therapies

12. Fibromyalgia Emerging Drugs and Latest Therapeutic Advances

13. Fibromyalgia Seven Major Market Analysis

14. Attribute Analysis

15. Fibromyalgia Market Outlook (In US, EU5, and Japan)

16. Fibromyalgia Companies Active in the Market

17. Fibromyalgia Access and Reimbursement Overview

18. KOL Views on the Fibromyalgia Market

19. Fibromyalgia Market Drivers

20. Fibromyalgia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Dermal Erythema Market

Dermal Erythema Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Dermal Erythema market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Dermal Erythema market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States